BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 38053464)

  • 1. Disease-Modifying Drugs Extend Survival in Hereditary Transthyretin Amyloid Polyneuropathy.
    Ueda M; Misumi Y; Nomura T; Tasaki M; Yamakawa S; Obayashi K; Yamashita T; Ando Y
    Ann Neurol; 2024 Feb; 95(2):230-236. PubMed ID: 38053464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease.
    Adams D; Koike H; Slama M; Coelho T
    Nat Rev Neurol; 2019 Jul; 15(7):387-404. PubMed ID: 31209302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis.
    Gertz MA; Scheinberg M; Waddington-Cruz M; Heitner SB; Karam C; Drachman B; Khella S; Whelan C; Obici L
    Expert Rev Clin Pharmacol; 2019 Aug; 12(8):701-711. PubMed ID: 31268366
    [No Abstract]   [Full Text] [Related]  

  • 4. Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology.
    Skrahina V; Grittner U; Beetz C; Skripuletz T; Juenemann M; Krämer HH; Hahn K; Rieth A; Schaechinger V; Patten M; Tanislav C; Achenbach S; Assmus B; Knebel F; Gingele S; Skrahin A; Hartkamp J; Förster TM; Roesner S; Pereira C; Rolfs A
    Ann Med; 2021 Dec; 53(1):1787-1796. PubMed ID: 34658264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Gene therapy options for hereditary transthyretin-related amyloidosis].
    Schilling M
    Nervenarzt; 2022 Jun; 93(6):557-565. PubMed ID: 35419654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Red flags and adjusted suspicion index for distinguishing hereditary transthyretin amyloid polyneuropathy from idiopathic axonal polyneuropathy.
    Warendorf JK; van der Star GM; Dooijes D; Notermans NC; Vrancken AFJE
    Neurol Sci; 2023 Oct; 44(10):3679-3685. PubMed ID: 37266816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The neuropathy in hereditary transthyretin amyloidosis: A narrative review.
    Tozza S; Severi D; Spina E; Iovino A; Aruta F; Ruggiero L; Dubbioso R; Iodice R; Nolano M; Manganelli F
    J Peripher Nerv Syst; 2021 Jun; 26(2):155-159. PubMed ID: 33960565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hereditary transthyretin amyloidosis in middle-aged and elderly patients with idiopathic polyneuropathy: a nationwide prospective study.
    Fargeot G; Echaniz-Laguna A; Labeyrie C; Svahn J; Camdessanché JP; Cintas P; Chanson JB; Esselin F; Piedvache C; Verstuyft C; Genestet S; Lagrange E; Magy L; Péréon Y; Sacconi S; Signate A; Nadaj-Pakleza A; Taithe F; Viala K; Tard C; Poinsignon V; Cauquil C; Attarian S; Adams D
    Amyloid; 2024 Mar; 31(1):62-69. PubMed ID: 37855400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis.
    Berends M; Brunger AF; Bijzet J; Kroesen BJ; Drost G; Lange F; Teunissen CE; In 't Veld S; Vrancken AF; Gans ROB; Hazenberg BPC; van der Zwaag PA; Nienhuis HLA
    Amyloid; 2024 Jun; 31(2):132-141. PubMed ID: 38477065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: Recommendations from a panel of experts.
    Karam C; Mauermann ML; Gonzalez-Duarte A; Kaku MC; Ajroud-Driss S; Brannagan TH; Polydefkis M
    Muscle Nerve; 2024 Mar; 69(3):273-287. PubMed ID: 38174864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chance or challenge, spoilt for choice? New recommendations on diagnostic and therapeutic considerations in hereditary transthyretin amyloidosis with polyneuropathy: the German/Austrian position and review of the literature.
    Dohrn MF; Auer-Grumbach M; Baron R; Birklein F; Escolano-Lozano F; Geber C; Grether N; Hagenacker T; Hund E; Sachau J; Schilling M; Schmidt J; Schulte-Mattler W; Sommer C; Weiler M; Wunderlich G; Hahn K
    J Neurol; 2021 Oct; 268(10):3610-3625. PubMed ID: 32500375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis.
    Louwsma J; Brunger AF; Bijzet J; Kroesen BJ; Roeloffzen WWH; Bischof A; Kuhle J; Drost G; Lange F; Kuks JBM; Gans ROB; Hazenberg BPC; Nienhuis HLA
    Amyloid; 2021 Mar; 28(1):50-55. PubMed ID: 32883119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diflunisal compassive use in transthyretin hereditary amyloid polyneuropathy: report of a first Spanish experience.
    Azorín SE; Cabib CE; Campistol JM
    Amyloid; 2017 Mar; 24(sup1):105-106. PubMed ID: 28434315
    [No Abstract]   [Full Text] [Related]  

  • 14. [Transthyretin familial amyloid polyneuropathy].
    Kopishinskaya SV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(10):82-89. PubMed ID: 30499502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays.
    Kaku MC; Bhadola S; Berk JL; Sanchorawala V; Connors LH; Lau KHV
    Amyloid; 2022 Sep; 29(3):184-189. PubMed ID: 35253562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis.
    Carroll A; Dyck PJ; de Carvalho M; Kennerson M; Reilly MM; Kiernan MC; Vucic S
    J Neurol Neurosurg Psychiatry; 2022 Jun; 93(6):668-678. PubMed ID: 35256455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three patients of transthyretin amyloidosis in a Japanese family with amyloidogenic transthyretin Thr49Ser (p.Thr69Ser) variant.
    Ikura H; Kitakata H; Endo J; Moriyama H; Sano M; Tsujikawa H; Sawano M; Masuda T; Ohki T; Ueda M; Kosaki K; Fukuda K
    Eur J Med Genet; 2022 Mar; 65(3):104451. PubMed ID: 35149236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transthyretin deposition in familial amyloidotic polyneuropathy.
    Saraiva MJ; Magalhaes J; Ferreira N; Almeida MR
    Curr Med Chem; 2012; 19(15):2304-11. PubMed ID: 22471982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis.
    Nie T; Heo YA; Shirley M
    Drugs; 2023 Oct; 83(15):1425-1432. PubMed ID: 37728865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic Strategies for Hereditary Transthyretin Amyloidosis].
    Ueda M
    Brain Nerve; 2023 May; 75(5):539-541. PubMed ID: 37194527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.